Ceribell, Inc. (CBLL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity maintained a Buy rating on the stock and has a $33.00 price target.
William Plovanic has given his Buy rating due to a combination of factors that highlight Ceribell, Inc.’s strong financial performance and strategic growth initiatives. The company reported impressive Q4/24 revenue of $18.5 million, which represents a 40.4% year-over-year increase and surpassed both the firm’s and consensus estimates. This growth was driven by higher-than-expected headband and Clarity (SaaS) revenues, indicating robust demand for Ceribell’s products.
Additionally, Ceribell’s management has projected a promising revenue outlook for FY25, with guidance in the range of $81 million to $85 million, aligning with analyst expectations. The company’s strategic expansion of its commercial team and investments in research and development, supported by an upsized IPO, are expected to drive further growth. Ceribell’s focus on becoming the standard of care in acute seizure management, along with its innovative technology and solid capital position, reinforces the Buy rating and the $33 price target.
Plovanic covers the Healthcare sector, focusing on stocks such as Nevro Corp, TransMedics Group, and CVRx. According to TipRanks, Plovanic has an average return of 4.7% and a 46.22% success rate on recommended stocks.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $32.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com